Instituto de Ensino e Pesquisa Clinica do Ceara

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes4 trials
• Chronic kidney disease2 trials
• Obesity2 trials
• Stroke2 trials
• Coronary artery disease1 trial
• Heart failure1 trial
• Peripheral artery disease1 trial

Phase

• Phase 35 trials

Status

• Active, not recruiting2 trials
• Not yet recruiting1 trial
• Recruiting1 trial
• Suspended1 trial

Lead sponsor

• Eli Lilly and Company4 trials
• Anji Pharma1 trial

Running trials

• Not yet recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

  NCT07900633· Phase 3· Eli Lilly and Company· Source

  Contact: Maria Cerqueira (principal investigator)

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

  Contact: Maria Cerqueira (principal investigator)

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

  NCT06297603· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease1 recruiting
• Obesity1 recruiting
• Stroke1 recruiting
• Type 2 diabetes1 recruiting